AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...
AstraZeneca plans to delist from Nasdaq and move to the NYSE, while its breast cancer drug Enhertu enters European regulatory ...
AstraZeneca has refuted allegations its staff “refuse to cooperate and respect” the U.K. marketing code. The drugmaker successfully defended itself against claims senior staff ignored requests to ...
AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S. for the treatment of patients with muscle-invasive ...
On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously ...
A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback